Pharmacology and Clinical Efficacy of Erdosteine in Chronic Obstructive Pulmonary Disease

Maurizio Moretti

Disclosures

Expert Rev Resp Med. 2007;1(3):307-316. 

In This Article

Five-Year View

Mucolytic agents decrease mucus viscoelastic properties, improve mucociliary clearance and decrease sputum production and appear designed to provide symptomatic relief to mucus hypersecretion in COPD. A recent systematic analysis of mucolytic agents concluded that these drugs, taken long term, could be very useful in patients who have repeated, prolonged or severe exacerbations of COPD. However, there is also increasing evidence that oxidative stress is involved in the pathogenesis of local lung inflammation, as well as in systemic phenomena, such as skeletal muscle dysfunction and, perhaps, even the increased cardiovascular risk of mortality that results from COPD. Hence, mucolytic agents with a specific antioxidative activity appear to be a logical approach to COPD therapy. In the next few years, clinical studies are needed to confirm, in COPD patients, the systemic effect shown by thiol agents in animal studies.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....